Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study
Verena Wally, Sophie Kitzmueller, Florian Lagler, Angelika Moder, Wolfgang Hitzl, Martin Wolkersdorfer, Peter Hofbauer, Thomas K Felder, Michael Dornauer, Anja Diem, Nora Eiler, Johann W Bauer, Verena Wally, Sophie Kitzmueller, Florian Lagler, Angelika Moder, Wolfgang Hitzl, Martin Wolkersdorfer, Peter Hofbauer, Thomas K Felder, Michael Dornauer, Anja Diem, Nora Eiler, Johann W Bauer
Abstract
Blistering in epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is associated with an inflammatory phenotype, which can be disrupted by diacerein in vitro. In this pilot study we hypothesized, that a topical formulation of diacerein 1% reduces blistering. Five patients initially applied diacerein underneath both armpits. Then, each participant received 1% diacerein-cream for one armpit, and placebo for the other (randomized withdrawal). The number of blisters was reduced significantly (left: -78%; right: -66% of baseline) within two weeks and remained significantly below the initial level even during withdrawal in four patients. These findings point to a relevant effect of diacerein and provide important information for a confirmative study.
Figures
References
- Morley SM, D'Alessandro M, Sexton C, Rugg EL, Navsaria H, Shemanko CS, Huber M, Hohl D, Heagerty AI, Leigh IM, Lane EB. Generation and characterization of epidermolysis bullosa simplex cell lines: scratch assays show faster migration with disruptive keratin mutations. Br J Dermatol. 2003;149:46–58. doi: 10.1046/j.1365-2133.2003.05493.x.
- Coulombe PA, Kerns ML, Fuchs E. Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility. J Clin Invest. 2009;119:1784–1793. doi: 10.1172/JCI38177.
- Wally V, Lettner T, Peking P, Peckl-Schmid D, Murauer EM, Hainzl S, Hintner H, Bauer JW. The pathogenetic role of interleukin-1 beta in severe epidermolysis bullosa simplex. J Invest Dermatol. 2013.
- Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1ß and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage. 2000;8:186–196. doi: 10.1053/joca.1999.0289.
- Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatol. 2006;45:129–138.
Source: PubMed